Horizon Discovery drives the application of gene editing and gene modulation within the global life science market – supporting scientists on the path from research to therapy.
CSC team worked closely with Horizon since IPO in 2014
Supporting corporate activity including 2014 IPO, acquisition of Dharmacon and other M&A, defence against hostile takeover attempt, leadership changes, divestment of business units
- Develop and implement all external and internal communications strategies and materials including for key international trade and
- Close work with management and board, providing sounding-board
- Media relations: relationships developed with key nationals, business and investment press
- Analyst relations: strong rapport built with covering & interested international analysts, regular calls and events held to maintain those relationships
Horizon is recognized as a leader in gene editing and modulation in the UK and internationally
Recommended all cash offer of £296m from PerkinElmer
More case studies
SparingVision is a genomic medicines company, translating pioneering science into vision-saving treatments.
CMR Surgical is developing next-generation robotic systems for minimal access surgery.
Immunocore is a leading T cell receptor (TCR) company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, through its pioneering soluble TCR technology platform.